BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31842180)

  • 1. PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?
    Chen S; Guenther LM; Aronhalt A; Cardillo L; Janeway KA; Church AJ
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):482-487. PubMed ID: 31842180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
    Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
    J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
    Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
    Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
    Xie L; Chen C; Liang X; Xu J; Sun X; Sun K; Yang R; Tang X; Guo W
    Orthop Surg; 2023 Mar; 15(3):829-838. PubMed ID: 36519392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
    Broos K; Lecocq Q; Raes G; Devoogdt N; Keyaerts M; Breckpot K
    Theranostics; 2018; 8(13):3559-3570. PubMed ID: 30026866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
    Marchevsky AM; Walts AE
    Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
    Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
    Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality.
    Gao W; Zhou J; Ji B
    DNA Cell Biol; 2017 Sep; 36(9):794-800. PubMed ID: 28650673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
    Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
    Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
    Yu W; Wang Y; Zhu J; Jin L; Liu B; Xia K; Wang J; Gao J; Liang C; Tao H
    Biomaterials; 2019 Feb; 192():128-139. PubMed ID: 30448697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.
    Zhang WJ; Peng CH; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):394-9. PubMed ID: 23924497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.